Cargando…
Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis
Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medicat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736933/ https://www.ncbi.nlm.nih.gov/pubmed/31506542 http://dx.doi.org/10.1038/s41598-019-49424-2 |
_version_ | 1783450576256761856 |
---|---|
author | Horii, Takeshi Iwasawa, Makiko Kabeya, Yusuke Atuda, Koichiro |
author_facet | Horii, Takeshi Iwasawa, Makiko Kabeya, Yusuke Atuda, Koichiro |
author_sort | Horii, Takeshi |
collection | PubMed |
description | Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medication PP and imperfect adherence were identified using multivariable logistic regression. PP was defined as using ≥6 medications. Patients with proportion of days covered (PDC) of <80% were defined as having poor medication adherence. A total of 884 patients were analysed. Multivariate analysis revealed that age, total number of consultations and body mass index (BMI) are factors that influence PP. Factors associated with PDC < 80% were 2–3, 4–5 and ≥ 6 medications compared with 1 medication, male sex, <17 consultations and age 50–59 and ≥ 60 years compared with <40 years. In conclusion, older age, high total number of consultations and BMI ≥ 25 kg/m(2) are risk factors for PP. PP influenced good medication adherence at the end of the observation period. |
format | Online Article Text |
id | pubmed-6736933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67369332019-09-20 Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis Horii, Takeshi Iwasawa, Makiko Kabeya, Yusuke Atuda, Koichiro Sci Rep Article Polypharmacy (PP) occurs in patients with type 2 diabetes (T2DM) owing to multimorbidity. We evaluated concomitant PP and medication adherence in T2DM 3 years after initiation of administration of a hypoglycaemic agent using a nationwide claim-based database in Japan. Factors associated with medication PP and imperfect adherence were identified using multivariable logistic regression. PP was defined as using ≥6 medications. Patients with proportion of days covered (PDC) of <80% were defined as having poor medication adherence. A total of 884 patients were analysed. Multivariate analysis revealed that age, total number of consultations and body mass index (BMI) are factors that influence PP. Factors associated with PDC < 80% were 2–3, 4–5 and ≥ 6 medications compared with 1 medication, male sex, <17 consultations and age 50–59 and ≥ 60 years compared with <40 years. In conclusion, older age, high total number of consultations and BMI ≥ 25 kg/m(2) are risk factors for PP. PP influenced good medication adherence at the end of the observation period. Nature Publishing Group UK 2019-09-10 /pmc/articles/PMC6736933/ /pubmed/31506542 http://dx.doi.org/10.1038/s41598-019-49424-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Horii, Takeshi Iwasawa, Makiko Kabeya, Yusuke Atuda, Koichiro Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title | Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title_full | Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title_fullStr | Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title_full_unstemmed | Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title_short | Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis |
title_sort | polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: a japanese database analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736933/ https://www.ncbi.nlm.nih.gov/pubmed/31506542 http://dx.doi.org/10.1038/s41598-019-49424-2 |
work_keys_str_mv | AT horiitakeshi polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis AT iwasawamakiko polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis AT kabeyayusuke polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis AT atudakoichiro polypharmacyandoralantidiabetictreatmentfortype2diabetescharacterisedbydrugclassandpatientcharacteristicsajapanesedatabaseanalysis |